Hellmich Silke, Schreiber Natalie, Fath Birgit, Hallek Michael
Kompetenznetz Maligne Lymphome e. V., Klinik I für Innere Medizin, Universitätsklinikum Köln, 50924, Köln, Deutschland.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Apr;59(4):454-64. doi: 10.1007/s00103-016-2316-9.
The Competence Network Malignant Lymphomas (KML), founded in 1999 at the initiative of the Federal Ministry of Education and Research (BMBF), brings together interdisciplinary medical and scientific expertise in research on malignant lymphomas. The network helps to release synergies in evidence-based clinical research and contributes to the accelerated transfer of advances in knowledge gained from therapeutic studies for the health care of lymphoma patients. During the regular BMBF funding period (1999-2009) individual sub-projects were hived off, such as the Cochrane Haematological Malignancies Group (CHMG) or the Scientific Institute of Haematologists and Oncologists in Private Practice (WINHO GmbH). At the end of BMBF funding, pivotal KML projects such as the reference diagnostic panel for KML lymphoma study groups, site management support, health care management and the information and communication section could be continued in the scientific association "Kompetenznetz Maligne Lymphome e. V." which was founded in 2005. Due to the recent in-depth understanding of the molecular and genetic mechanisms of lymphomagenesis and the consequent transformation to precision medicine targeting specialised groups of patients, the KML is currently facing the challenge of developing modern study, health-care and information concepts in ever shorter periods of time.
恶性淋巴瘤能力网络(KML)于1999年在联邦教育与研究部(BMBF)的倡议下成立,汇集了恶性淋巴瘤研究方面的跨学科医学和科学专业知识。该网络有助于在循证临床研究中释放协同效应,并促进将治疗研究中获得的知识进展加速转化,以用于淋巴瘤患者的医疗保健。在BMBF的常规资助期(1999 - 2009年)内,个别子项目被剥离出去,比如Cochrane血液恶性肿瘤小组(CHMG)或私人执业血液学家和肿瘤学家科学研究所(WINHO有限公司)。在BMBF资助结束时,KML的关键项目,如KML淋巴瘤研究小组的参考诊断小组、站点管理支持、医疗保健管理以及信息与交流部门,可以在2005年成立的科学协会“Kompetenznetz Maligne Lymphome e. V.”中继续开展。由于最近对淋巴瘤发生的分子和遗传机制有了更深入的了解,并因此转向针对特定患者群体的精准医学,KML目前面临着在更短时间内开发现代研究、医疗保健和信息概念的挑战。